Literature DB >> 26795414

Intravitreal fluocinolone acetonide (Iluvien) for treatment of refractory diabetic macular oedema in vitrectomised eyes.

A Kumar1, Q Alfahad1, A Mitra1, S Elsherbiny1, P L Lip1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26795414      PMCID： PMC4869125          DOI： 10.1038/eye.2015.281

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.

Authors:  Joan-En Chang-Lin; James A Burke; Qing Peng; Ton Lin; Werhner C Orilla; Corine R Ghosn; Kai-Ming Zhang; Baruch D Kuppermann; Michael R Robinson; Scott M Whitcup; Devin F Welty
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-28       Impact factor: 4.799

2.  Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.

Authors:  David S Boyer; David Faber; Sunil Gupta; Sunil S Patel; Homayoun Tabandeh; Xiao-Yan Li; Charlie C Liu; Jean Lou; Scott M Whitcup
Journal:  Retina       Date:  2011-05       Impact factor: 4.256

3.  Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes.

Authors:  Alissar Nehmé; Jeffrey Edelman
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05       Impact factor: 4.799

4.  Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema.

Authors:  Marta S Figueroa; Inés Contreras; Susana Noval
Journal:  Retina       Date:  2008-03       Impact factor: 4.256

5.  Vitreous VEGF clearance is increased after vitrectomy.

Authors:  Susan S Lee; Corine Ghosn; Zhiling Yu; Leandro C Zacharias; Henry Kao; Carmine Lanni; Natania Abdelfattah; Baruch Kuppermann; Karl G Csaky; David Z D'Argenio; James A Burke; Patrick M Hughes; Michael R Robinson
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-17       Impact factor: 4.799
  5 in total
  4 in total

Review 1.  Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema.

Authors:  Yahiya Y Syed
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

2.  Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.

Authors:  A Meireles; C Goldsmith; I El-Ghrably; A Erginay; M Habib; B Pessoa; J Coelho; T Patel; R Tadayoni; P Massin; J Atorf; A J Augustin
Journal:  Eye (Lond)       Date:  2017-01-13       Impact factor: 3.775

3.  Report of 12-months efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: a real-world result in the United Kingdom.

Authors:  F Alfaqawi; P L Lip; S Elsherbiny; R Chavan; A Mitra; B Mushtaq
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

Review 4.  Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review.

Authors:  William Fusi-Rubiano; Rebecca R Blow; Mark Lane; Rupal Morjaria; Alastair K Denniston
Journal:  Ophthalmol Ther       Date:  2018-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.